Best Small Cap Stocks to Trade

Small Cap Stock Alerts in Real Time | No one provides consistent winners like Broad Street!

Mar 22 2016

Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial and Operating Results Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)

Conference Call Today at 5 p.m. EST

– ALD403 12-Week Phase 2b Chronic Migraine and Phase 1 Self-Administration Top-line Data Expected First Quarter 2016 –

BOTHELL, Wash., Feb. 23, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Congenital Adrenal Hyperplasia, Cushing’s Disease and autoimmune and inflammatory diseases, today provided a corporate update and reported its financial results for the fourth quarter and full year ended Dec. 31, 2015.

“Our focus this year remains on the accelerated development of ALD403, Alder’s pivotal-stage migraine prevention candidate with the potential to deliver migraine-free relief to patients living with migraine. Expected progress this year includes ongoing enrollment in our first pivotal trial, PROMISE 1 as well as top-line data read-outs later this quarter from our Phase 2b chronic migraine study and our multiple dose Phase 1 study evaluating quarterly self-injectable administration of ALD403,” said Randall C. Schatzman, Ph.D., president and chief executive officer of Alder. “In addition, we plan to initiate our next pivotal study, PROMISE 2, in the second half of 2016. As we continue our clinical momentum for ALD403, we will also continue to expand our team and establish a strong foundation to support a future FDA filing and ultimately commercialization to meet the critical unmet need of the 13 million patients who are migraine prevention candidates, including the three million patients suffering from chronic migraine.”

2015 and Recent Corporate Highlights

ALD403 — Pivotal-stage novel monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) for the prevention of migraine

  • Initiated PROMISE 1 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy 1), the first of two planned pivotal clinical trials intended to support a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). PROMISE 1 is a double-blind, randomized, placebo-controlled, multi-dose trial, evaluating the efficacy and safety of three dose levels of ALD403 in patients with frequent episodic migraine. This planned 600-patient trial is currently enrolling and top-line data are expected in the first half of 2017.
  • Completed enrollment and dosing in the ongoing 600-patient Phase 2b double-blind, randomized, placebo-controlled, dose-ranging clinical trial of ALD403 evaluating patients with chronic migraine. Top-line 12-week data are expected by the end of the first quarter of 2016. 24-week data from this trial are expected in the middle of 2016.
  • Completed enrollment and dosing in an ongoing Phase 1 placebo-controlled, multi-dose, clinical trial evaluating the pharmacokinetics and pharmacodynamics of two quarterly doses of ALD403 aimed at quarterly dosing via self-administration in healthy volunteers. Top-line data are expected by the end of the first quarter of 2016.

ALD1613 — Novel monoclonal antibody that inhibits adrenocorticotropic hormone (ACTH)

  • ALD1613 has the potential to treat patients with Congenital Adrenal Hyperplasia and Cushing’s Disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies; an IND filing with the FDA is planned for 2016.

Clazakizumab — Novel monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin 6 (IL-6), an important driver of the inflammatory response

  • Clazakizumab met its primary endpoint in a second Phase 2b dose-ranging clinical trial in adults with moderate to severe rheumatoid arthritis who experienced an inadequate response to TNF inhibitors. Strategic alternatives to further develop clazakizumab and leverage its ability to effectively inhibit IL-6 are actively being pursued.

Corporate

  • Completed two public offerings of common stock in 2015 with total net proceeds of approximately $406.6 million.
  • Appointed two biotechnology veterans, Paul R. Carter, executive vice president, Commercial Operations at Gilead Sciences, Inc., and Paul B. Cleveland, chief executive officer of Avalanche Biotechnologies, Inc. to the Board of Directors.
  • Announced senior appointments of industry veterans to strengthen and expand Alder’s leadership team to support the advancement of ALD403 toward future commercialization: James B. Bucher, J.D., as senior vice president & general counsel, Mary Tou as vice president of commercial strategy, Annette Vahratian as vice president of quality and David A. Walsey as vice president of corporate communications.

Expected 2016 Events and Milestones

  • Announce top-line 12-week data from the 600-patient Phase 2b double-blind, randomized, placebo-controlled, dose-ranging clinical trial of ALD403 in chronic migraine patients by the end of the first quarter of 2016.
  • Announce top-line 12 and 24-week data from the Phase 1 placebo-controlled, multi-dose, clinical trial of ALD403 aimed at quarterly self-administration in healthy volunteers by the end of the first quarter of 2016.
  • Announce top-line 24-week data from the 600-patient Phase 2b double-blind, randomized, placebo-controlled, dose-ranging clinical trial of ALD403 in chronic migraine patients mid-year 2016.
  • Initiate PROMISE 2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy 1) in patients with chronic migraine as the second of the two planned pivotal clinical trials intended to support a BLA submission to the FDA for ALD403 in the second half of 2016.
  • Initiate late stage clinical development of a self-injected formulation of ALD403 following completion of the Phase 1 trial.
  • Submit an IND application to the FDA for ALD1613, a genetically engineered monoclonal antibody designed to specifically inhibit adrenocorticotropic hormone (ACTH) focusing on two orphan diseases: Congenital Adrenal Hyperplasia and Cushing’s Disease.

Fourth Quarter and Year-End 2015 Financial Results

As of December 31, 2015, Alder had $381.0 million in cash and cash equivalents, short-term and long-term investments, compared to $408.2 million as of Sept. 30, 2015 and compared to $55.9 million as of December 31, 2014.

For the quarter and for the full year ended December 31, 2015, Alder did not record any revenues compared to $6.4 million for the fourth quarter of 2014 and compared to $54.7 million for the year ended December 31, 2014. Revenues in 2014 were primarily derived from our clazakizumab collaboration with Bristol-Myers Squibb Company, which terminated in December 2014.

Research and development expenses for the quarter ended December 31, 2015 totaled $21.6 million, compared to $10.0 million for the same period in 2014. For the full year 2015, research and development expenses totaled $69.6 million, compared to $33.4 million for 2014. The increases in spending for both periods were primarily due to the ALD403 program, and consisted of costs related to the ongoing chronic migraine clinical trial, the initiation of the PROMISE 1 clinical trial and manufacturing costs of drug supplies for existing and planned pivotal clinical trials.  In addition, Alder incurred costs for IND-enabling activities for ALD1613 and increased compensation costs related to an increase in research and development headcount to support Alder’s R&D activities.

General and administrative expenses for the quarter ended December 31, 2015 totaled $4.8 million, compared to $3.4 million for the same period in 2014. The increase in the fourth quarter of 2015 was primarily due to increased stock-based compensation costs. For the full year 2015, general and administrative expenses totaled $16.7 million, compared to $12.5 million for 2014.  The increase in the 2015 period was due to an increase in headcount, as well as increases in market research and other administrative costs.

Net loss for the quarter ended December 31, 2015 totaled $26.2 million, or $0.60 per share, compared to net loss of $6.9 million, or $0.22 per share on a fully-diluted basis, for the same period in 2014. For the full year 2015, net loss totaled $85.5 million, or $2.11 per share on a fully-diluted basis, compared to net income of $8.9 million, or $0.30 per share, for 2014. The 2014 net income was primarily derived from revenue recognized under Alder’s collaboration with Bristol-Myers Squibb Company, which terminated in December 2014.

Conference Call and Webcast

Alder will host a conference call today at 5:00 p.m. EST to discuss these financial results and recent corporate highlights. The live call may be accessed by dialing (866) 888-8633 for domestic callers or (216) 672-4398 for international callers, and providing conference ID number 40337572. The webcast will be broadcast live on the investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder’s lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder’s second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of Congenital Adrenal Hyperplasia and Cushing’s Disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, clazakizumab is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab. For more information, please visit http://www.alderbio.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403, ALD1613 and clazakizumab; the initiation of future clinical trials and studies; the availability of clinical trial data; future regulatory filings; patient enrollment; the expansion of Alder’s team; and the pursuit of strategic alternatives for clazakizumab.  Words such as “expected,” “potential,” “will,” “continue,” “plan,” “announce,” “further,” “seeking,” “initiate,” “submit,” “intended,” “designed,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder’s current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403, ALD1613 and clazakizumab to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403, ALD1613 and clazakizumab; risks and uncertainties related to regulatory review and approval processes and Alder’s compliance with applicable legal and regulatory requirements; the uncertain timing and level of expenses associated with the development of ALD403, ALD1613 and clazakizumab; the sufficiency of Alder’s capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the quarter and year ended December 31, 2015, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2016, and is available on the SEC’s website at www.sec.gov.  Additional information will also be set forth in our other reports and filings we will make with the SEC from time to time.  The forward-looking statements made in this press release speak only as of the date of this press release.  Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Condensed Consolidated Balance Sheets
(Unaudited)
(Amounts in thousands)
December 31, December 31,
 2015  2014
Cash, cash equivalents and investments $   381,012 $   55,872
Prepaid expenses and other assets 19,015 8,487
Total assets $   400,027 $   64,359
Total liabilities $   12,510 $   5,202
Total stockholders’ equity   387,517   59,157
Total liabilities and stockholders’ equity $   400,027 $   64,359

 

Condensed Consolidated Statements of Operations
(Unaudited)
(Amounts in thousands, except share and per share data)
Three Months Ended Year Ended
December 31, December 31,
 2015  2014  2015  2014
Revenues
Collaboration and license agreements  $ — $   6,436 $ — $   54,705
Operating expenses
Research and development   21,636 9,995   69,611 33,439
General and administrative   4,793 3,408   16,718 12,462
Total operating expenses   26,429   13,403   86,329 45,901
Income (loss) from operations   (26,429 ) (6,967 )   (86,329 ) 8,804
Total other income   264 25   859 104
Net income (loss) $   (26,165 ) $   (6,942 ) $   (85,470 ) $   8,908
Net income (loss) per share – basic $   (0.60 ) $   (0.22 ) $   (2.11 ) $   0.43
Net income (loss) per share –  diluted $   (0.60 ) $   (0.22 ) $   (2.11 ) $   0.30
Weighted average number of common shares used in net income (loss) per share – basic 43,649,894 30,893,040 40,586,980 20,506,565
Weighted average number of common shares used in net income (loss) per share – diluted 43,649,894 30,893,040 40,586,980 29,427,287

 

 

 

Media Contacts:		
David Schull or Lena Evans	
Russo Partners, LLC		
(212) 845-4271			
(212) 845-4262			
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

Investor Relations Contact:
David Walsey
Alder Biopharmaceuticals
(425) 408-8032
dwalsey@alderbio.com

Written by broadAdmin · Categorized: Uncategorized

Privacy Policy and Disclaimer

Transparency is very important to us.

Please view our full privacy policy and disclaimer below.

 

 

 

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and SMS messages to you.
Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may reply to this email.
Disclaimer
BroadStreetAlerts. com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
This website / media webpage is owned, operated, and edited by Small Cap Specialists LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “SCS LLC” refers to Small Cap Specialists LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. SCS LLC’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online or Phone Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are purely for the purpose of building our brands. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.
Please Note: SCS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator’s , owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.
All information on featured companies is provided by the companies profiled or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
SCS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
SCS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

 

Most Publicly Traded Companies Engage in Some Form of Paid Media, Investor Relations and Advertising. 

Copyright © 2023 · Broad Street Alerts · All Rights Reserved

Manage Cookie Consent
We use cookies to optimize our website and your experience.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}